• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SeaSpine to Report Second Quarter 2021 Financial Results on August 2, 2021

    7/26/21 4:05:00 PM ET
    $SPNE
    Medical Specialities
    Health Care
    Get the next $SPNE alert in real time by email

    CARLSBAD, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release second quarter financial results after the close of trading on Monday, August 2, 2021. Members of the Company's management team will host a corresponding conference call and webcast beginning at 2:00 pm PT / 5:00 pm ET.

    Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 1257053. To listen to a live webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com.

    About SeaSpine

    SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products and enabling technologies that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants and software product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

    Investor Relations Contact

    Leigh Salvo

    (415) 937-5402

    [email protected]



    Primary Logo

    Get the next $SPNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPNE

    DatePrice TargetRatingAnalyst
    11/2/2022$12.00 → $6.75Buy → Hold
    Truist
    4/22/2022$27.00 → $21.00Overweight
    Cantor Fitzgerald
    4/13/2022$20.00Buy
    Truist
    12/21/2021$25.00 → $20.00Buy
    Truist Securities
    10/28/2021$100.00Buy
    Loop Capital
    More analyst ratings

    $SPNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SeaSpine Announces 100th Placement of 7D FLASH™ Navigation System

      CARLSBAD, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the placement of its 100th 7D FLASH™ Navigation System globally. The 7D FLASH™ Navigation System uses visible light to create a three-dimensional image for surgical navigation in just seconds, which is expected to result in shorter and more efficient spinal procedures with less radiation exposure. It is the only marketed image-guidance system that utilizes novel and proprietary camera-based technology, coupled with machine-vision algorithms, to eliminate the long-standing fru

      12/27/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

      Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221118005106/en/ Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Sen

      11/18/22 7:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

      LEWISVILLE, Texas and CARLSBAD, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Senior Vice President from 2015 through 2022, and as

      11/18/22 7:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities

    $SPNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Stephenson Kirtley C. returned 138,340 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:21:07 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 4: Steinway Angela returned 23,725 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:20:51 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 4: Maniar Shweta returned 23,993 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:20:35 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    SEC Filings

    See more
    • SEC Form CT ORDER filed by SeaSpine Holdings Corporation

      CT ORDER - SeaSpine Holdings Corp (0001637761) (Filer)

      4/3/23 8:19:25 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 15-12G filed by SeaSpine Holdings Corporation

      15-12G - SeaSpine Holdings Corp (0001637761) (Filer)

      1/17/23 4:31:53 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by SeaSpine Holdings Corporation

      EFFECT - SeaSpine Holdings Corp (0001637761) (Filer)

      1/12/23 12:15:22 AM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SeaSpine downgraded by Truist with a new price target

      Truist downgraded SeaSpine from Buy to Hold and set a new price target of $6.75 from $12.00 previously

      11/2/22 6:34:40 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Cantor Fitzgerald resumed coverage on SeaSpine with a new price target

      Cantor Fitzgerald resumed coverage of SeaSpine with a rating of Overweight and set a new price target of $21.00 from $27.00 previously

      4/22/22 9:10:58 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Truist resumed coverage on SeaSpine with a new price target

      Truist resumed coverage of SeaSpine with a rating of Buy and set a new price target of $20.00

      4/13/22 7:17:39 AM ET
      $SPNE
      Medical Specialities
      Health Care